Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Sparks, Jeffrey A; Wallace, Zachary S; Seet, Andrea M; Gianfrancesco, Milena A; Izadi, Zara; Hyrich, Kimme L; Strangfeld, Anja; Gossec, Laure; Carmona, Loreto; Mateus, Elsa F; Lawson-Tovey, Saskia; Trupin, Laura; Rush, Stephanie; Katz, Patricia; Schmajuk, Gabriela; Jacobsohn, Lindsay; Wise, Leanna; Gilbert, Emily L; Duarte-García, Ali; Valenzuela-Almada, Maria O; Pons-Estel, Guillermo J; Isnardi, Carolina A; Berbotto, Guillermo A; Hsu, Tiffany Y -T; D'Silva, Kristin M; Patel, Naomi J; Kearsley-Fleet, Lianne; Schäfer, Martin; Ribeiro, Sandra Lúcia Euzébio; Al Emadi, Samar; Tidblad, Liselotte; Scirè, Carlo Alberto; Raffeiner, Bernd; Thomas, Thierry; Flipo, René-Marc; Avouac, Jérôme; Seror, Raphaèle; Bernardes, Miguel; Cunha, Maria Margarida; Hasseli, Rebecca; Schulze-Koops, Hendrik; Müller-Ladner, Ulf; Specker, Christof; Souza, Viviane Angelina de; Mota, Licia Maria Henrique da; Gomides, Ana Paula Monteiro; Dieudé, Philippe; Nikiphorou, Elena; Kronzer, Vanessa L; Singh, Namrata

doi:10.1136/annrheumdis-2021-220418

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). Methods We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021).…